Jacob B Leary, Thomas Enright, Dimitra Rafailia Bakaloudi, Alina Basnet, Gennady Bratslavsky, Joseph Jacob, Philippe E Spiess, Roger Li, Andrea Necchi, Ashish M Kamat, Dean C Pavlick, Natalie Danziger, Richard S P Huang, Douglas I Lin, Liang Cheng, Jeffrey Ross, Rafee Talukder, Petros Grivas
BACKGROUND: Human epidermal growth factor-2 (HER2) overexpression is an oncogenic driver in many solid tumors, including urothelial bladder cancer (UBC). In addition, activating mutations in the ERBB2 gene have been shown to play an oncogenic role similar to ERBB2 amplification. OBJECTIVE: To describe and compare the frequency and nature of genomic alterations (GA) of ERBB2-altered (mutations, amplification) and ERBB2 wild-type UBC. PATIENTS AND METHODS: Using a hybrid capture-based comprehensive profiling assay, 9518 UBC cases were grouped by ERBB2 alteration and evaluated for all classes of genomic alterations (GA), tumor mutational burden (TMB), microsatellite instability (MSI), genome-wide loss of heterozygosity (gLOH), and genomic mutational signature...
April 3, 2024: Targeted Oncology